Abstracts tagged "Disease Activity"

Abstract Number: 1416 • 2016 ACR/ARHP Annual Meeting
Sustained Improvement in Documentation of Disease Activity Measurement As a Quality Improvement Project at an Academic Rheumatology Clinic
Melissa Wells¹, Rebecca Sadun², Malithi Jayasundara¹, Nicholas Holdgate¹, Samya Mohammad¹, Jason Weiner¹, Tayseer Haroun¹, Stephen Balevic², Lisa Criscione-Schrieber¹ and Mala Kaul¹, ¹Rheumatology, Duke University Medical Center, Durham, NC, ²Rheumatology Adult and Pediatric, Duke University Medical Center, Durham, NC
Background/Purpose: Measurement of disease activity is considered a quality measure for management of rheumatoid arthritis (RA) patients. One validated measure of RA disease activity is…
Abstract Number: 1696 • 2016 ACR/ARHP Annual Meeting
Minimal Disease Activity Is a Stable Measure of Therapeutic Response in Psoriatic Arthritis Patients Receiving Treatment with Adalimumab
Frank Behrens¹, Michaela Koehm², Eva Christina Schwaneck³, Marc Schmalzing⁴, Holger Gnann⁵, Gerd Greger⁶, Hans-Peter Tony⁷ and Harald Burkhardt¹, ¹Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt, Germany, ²Division of Rheumatology and Fraunhofer IME-Project-Group Translational Medicine and Pharmacology, Goethe University, Frankfurt/Main, Germany, ³Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Wuerzburg, Germany, ⁴Rheumatology/Clinical Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany, ⁵Abteilung Biostatistik, GKM Gesellschaft für Therapieforschung mbH, München, Germany, ⁶AbbVie Deutschland GmbH & Co.KG, Wiesbaden, Germany, ⁷Rheumatology/Immunology, Medical Clinic II, University Clinic Wuerzburg, Würzburg, Germany
Background/Purpose: Minimal disease activity (MDA) is an important goal for patients with rheumatologic disorders, including psoriatic arthritis (PsA). The assessment of MDA could potentially help…
Abstract Number: 2004 • 2016 ACR/ARHP Annual Meeting
Is Disease Activity Associated with Work Productivity Loss, Presenteeism and Absenteeism in Patients with Early Axial Spondyloarthritis? Results from the Spondyloarthritis Caught Early (SPACE)-Cohort
Miranda van Lunteren¹, Pauline Bakker¹, Zineb Ez-Zaitouni¹, Camilla Fongen², Robert Landewé³, Maikel van Oosterhout⁴, Roberta Ramonda⁵, Floris van Gaalen¹ and Désirée van der Heijde¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology, Academic Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁵Rheumatology Unit, University of Padova, Padova, Italy
Background/Purpose: Disease activity has an important impact on work productivity in patients with Ankylosing Spondylitis (AS). However, if and to what extent this is the…
Abstract Number: 2499 • 2016 ACR/ARHP Annual Meeting
Tocilizumab Achieves Rapid Reduction of Disease Activity and Has Beneficial Effects on Bone Mineral Density in Patients with Rheumatoid Arthritis
Maria Hoehle, Rheumatology, Hamburg, Germany
Tocilizumab achieves rapid reduction of disease activity and has beneficial effects on bone mineral density in patients with rheumatoid arthritis Maria Höhle, MD11Orthopedic, Medical, Rheumatologic…
Abstract Number: 2738 • 2016 ACR/ARHP Annual Meeting
The Effect of Pregnancy on Disease Activity Outcomes in Psoriatic Arthritis Patients
Mark Berman¹, Daphna Paran¹, Yonatan Wolman¹ and Ori Elkayam², ¹Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, ²Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel
Background/Purpose : Psoriatic arthritis(PsA) often affects patients at a childbearing age. The relationship between pregnancy and PsA, in terms of pregnancy outcomes and its effect on…
Abstract Number: 2991 • 2016 ACR/ARHP Annual Meeting
A Molecular Signature Based on IFN Gene Signature and Serology Defines Two Populations of Patients with Different Baseline Disease Activity in a Large Multinational Phase 3 SLE Trial Population
Michelle Petri¹, Kenneth C. Kalunian², Murray Urowitz³, David A. Isenberg⁴, Richard Furie⁵, MaryAnn Morgan-Cox⁶, Maria Silk⁷, Ernst R. Dow⁸, Richard Higgs⁷, Steven Watts⁷ and Matthew D Linnik⁹, ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Division of Rheumatology, Allergy & Immunology, UCSD School of Medicine Center for Innovative Therapy, La Jolla, CA, ³Medicine, Toronto Western Hospital and University of Toronto, Toronto, ON, Canada, ⁴Centre for Rheumatology, Division of Medicine, University College London, London, United Kingdom, ⁵North Shore University Hospital, Great Neck, NY, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷Eli Lilly, Indianapolis, IN, ⁸Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, IN, ⁹Immunology, Lilly Biotechnology Center, San Diego, CA
Background/Purpose: Registration trials for SLE therapeutics require large numbers of patients with active disease, which in turn necessitates the trials be multinational with many participating…
Abstract Number: 427 • 2015 ACR/ARHP Annual Meeting
The Impact of Biologic Agent Initiation after 1 Versus 2 Prior Csdmards in Patients with Rheumatoid Arthritis
Dimitrios A. Pappas^1,2, Jenny Griffith³, Chitra Karki², Mei Liu⁴, Joel M. Kremer⁵, Arijit Ganguli³ and Jeffrey D. Greenberg^2,6, ¹Columbia University, New York, NY, ²Corrona, LLC, Southborough, MA, ³AbbVie Inc., North Chicago, IL, ⁴352 Turnpike Rd, Corrona, LLC, Southborough, MA, ⁵Albany Medical College and The Center for Rheumatology, Albany, NY, ⁶NYU School of Medicine, New York, NY
Background/Purpose: Patients with Rheumatoid Arthritis (RA) who don’t respond to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs) should be treated with biologic agents(1). The objective…
Abstract Number: 668 • 2015 ACR/ARHP Annual Meeting
Pasdas, Cpdai and MDA Evolution in the First 6 Months after Diagnosis of Early Psoriatic Arthritis Patients: Results of the Depar Study
Jolanda Luime¹, Ilja Tchetverikov², Marijn Vis³, Cathelyne Appels⁴, Wiebo van der Graaff⁵, Josien Veris⁶, Andreas Gerards⁷, Hans van Groenendaal⁸, Mark Kok⁹, Lindy-Anne Korswagen¹⁰, Cor Stolk¹¹ and Cicero, ¹Department of Rheumatology, Erasmus Medical Centre, Rotterdam, Netherlands, ²Albert Schweitzer Ziekenhuis, Dordrecht, Netherlands, ³Rheumatology, ErasmusMC, Rotterdam, Netherlands, ⁴Rheumatology, Amphia Hospital, Breda, Netherlands, ⁵Rheumatology, Rivas hospital, Gorinchem, Netherlands, ⁶Rheumatology, Reumazorg Zuid West Nederland, Goes, Netherlands, ⁷Rheumatology, Vlietland Hospital, Schiedam, Netherlands, ⁸Rheumatology, Reumazorg Zuid West Nederland, Roosendaal, Netherlands, ⁹Maasstadweg 21, Maasstad Ziekenhuis, Rotterdam, Netherlands, ¹⁰Rheumatology, Sint Fransicus Gasthuis, Rotterdam, Netherlands, ¹¹-, Patient Partner, Bunnink, Netherlands
Background/Purpose: Several disease activity measures were developed for use in psoriatic arthritis (PsA) . Little data is available on their performance in usual care. This…
Abstract Number: 1072 • 2015 ACR/ARHP Annual Meeting
Baseline Gene Expression Profiles in 1760 Patients from Two Phase III Trials of BAFF/BLyS Blockade in SLE
Robert W Hoffman¹, Joan T Merrill², Marta E. Marta Alarcón Riquelme³, Michelle Petri⁴, Ernst R Dow⁵, Eric Nantz⁶, Laura K Nisenbaum⁵, Krista M Schroeder⁶, Wendy J Komocsar⁶, Narayanan B Perumal⁵, Matthew D Linnik⁶, Guilherme V Rocha⁶ and Richard E Higgs⁶, ¹Immunology-Medical, Eli Lilly and Company, Indianapolis, IN, ²OMRF, Oklahoma, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁴Johns Hopkins Lupus Center, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Eli Lilly and Company, Indiananpolis, IN, ⁶Eli Lilly and Company, Indianapolis, IN
Background/Purpose: Elevated Type-I interferon (IFN) signature characterizes at least 50% of adults with SLE and has been associated with autoantibodies and more severe disease in…
Abstract Number: 1743 • 2015 ACR/ARHP Annual Meeting
Gender Differences in Ankylosing Spondylitis: Men Derive Greater Benefit from Tumor Necrosis Factor Alpha Inhibitors
Jennifer Mandal¹, Michael M. Ward², Michael Weisman³, Jillian Simard⁴, Matthew A. Brown⁵, MinJae Lee⁶, Mohammad H. Rahbar⁷, John D. Reveille⁸ and Lianne S. Gensler⁹, ¹Medicine, University of California San Francisco, San Francisco, CA, ²NIH/NIAMS, Bethesda, MD, ³Cedars-Sinai Medical Center, Los Angeles, CA, ⁴University of California San Francisco, San Francisco, CA, ⁵The University of Queensland Diamantina Institute, Brisbane, Australia, ⁶Biostatistics/Epidemiology/Research Design (BERD) Core | Center for Clinical and Translational Sciences, University of Texas Health Science Center at Houston, Houston, TX, ⁷The University of Texas Health Science Center at Houston, Houston, TX, ⁸Rheumatology, University of Texas Health Science Center at Houston, Houston, TX, ⁹Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: Ankylosing spondylitis (AS) manifests differently in men and women. Women with AS have less severe radiographic disease, yet tend to report more severe symptoms.…
Abstract Number: 2490 • 2015 ACR/ARHP Annual Meeting
Implementation of Disease Activity Measurement for Rheumatoid Arthritis Patients in an Academic Rheumatology Clinic
Alison Bays¹, Elizabeth R. Wahl², David I. Daikh³, Jinoos Yazdany⁴ and Gabriela Schmajuk⁵, ¹Rheumatology, University of Washington, Seattle, WA, ²Medicine/Rheumatology, San Francisco Veterans Affairs Medical Center, San Francisco, CA, ³Rheumatology, UCSF/VA Medical Center, San Francisco, CA, ⁴Rheumatology, UCSF, SF, CA, ⁵San Francisco VA Medical Center, University of California, San Francisco, San Francisco, CA
Background/Purpose: Current recommendations for optimal rheumatoid arthritis (RA) management include routine assessment of disease activity and adjustment of medication to achieve remission or low disease…
Abstract Number: 2643 • 2015 ACR/ARHP Annual Meeting
Decreased Pain Level with Aging Leads to Underestimation of Disease Activity in Rheumatoid Arthritis
Yong Gil Hwang¹, Juan (June) Feng², Heather Eng³, Jason Lyons⁴, Anthony Fabio⁵ and Larry W. Moreland⁶, ¹Department of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Epidemiology Data Center, University of Pittsburgh, Graduate School of Public Health, Pittsburgh, PA, ³Epidemiology, Univ of Pittsburgh, Pittsburgh, PA, ⁴School of Public Health, Department of Epidemiology, University of Pittsburgh, Pittsburgh, PA, ⁵Department Of Epidemiology, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) is most prevalent in those who are 60 years of age or older. It has not been clearly established whether…
Abstract Number: 2901 • 2015 ACR/ARHP Annual Meeting
Anti-dsDNA Antibodies Measured By Chemiluminescent Immunoassay Show Strong Association with Active Lupus Nephritis
Gabriella Lakos¹, John G. Hanly², Peter Martis¹, Chelsea Bentow¹, Milagros Garcia³, Odette Viñas³, Gerard Espinosa⁴, Ricard Cervera⁴ and Michael Mahler⁵, ¹Research, Inova Diagnostics, San Diego, CA, ²Rheumatology, Division of Rheumatology, Capital Health and Dalhousie University, Halifax, NS, Canada, ³Immunology, Hospital Clinic of Barcelona, Barcelona, Spain, ⁴Department of Autoimmune Diseases, Hospital Clínic, Barcelona, Spain, ⁵Inova Diagnostics, San Diego, CA
Background/Purpose: Anti-dsDNA antibodies support the diagnosis of systemic lupus erythematosus (SLE), and their quantification is useful for the assessment of lupus nephritis (LN) and the…
Abstract Number: 3257 • 2015 ACR/ARHP Annual Meeting
The Link Between DAS28 and the Short-Term Risk of Acute Coronary Syndrome in RA, and Its Driving Factors
Lotta Ljung^1,2, Thomas Frisell³ and Johan Askling^3,4, ¹Department of Medicine, Solna, Clinical epidemiology unit, Karolinska Institutet, Stockholm, Sweden, ²Department for Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, ³Clinical Epidemiology Unit, Department of Medicine, Karolinska Institutet, Stockholm, Sweden, ⁴Rheumatology Unit, Rheumatology Unit, Karolinska University Hospital, Stockholm, Sweden
Background/Purpose: The extent to which a short-term effect of the disease activity adds to the over-risk of coronary events in patients with Rheumatoid Arthritis (RA)…
Abstract Number: 457 • 2015 ACR/ARHP Annual Meeting
RA Patients with Medicare Only Insurance Have Similar Clinical Outcomes As Patients with Private Insurance Despite Having Less Access to Biologics
Marcia S. Genta¹, Amnon Sonnenberg² and Robert M. Genta³, ¹Dallas Arthritis Center, Dallas, TX, ²Medicine - Gastroenterology, Portland VAMC - Oregon Health & Science University, Portland, OR, ³Laboratory, Dallas Arthritis Center, Dallas, TX
Background/Purpose: We have previously shown that patients with Medicare only coverage without financial assistance from foundations were significantly less likely to receive Biologics than patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].